Table 1 Patient Characteristics (N = 357)
From: The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
Characteristic | Patients |
|---|---|
N (%) | |
Age, median (range) | |
Sex | |
Male | 214 (60) |
Female | 143 (40) |
ECOG performance status 0-1 | 326 (91) |
Primary tumor location | |
Gastroesophageal junction/proximal stomach | 107 (30) |
Mid to distal stomach | 231 (65) |
Unclassifiable/Unknown | 19 (5) |
Disease status | |
Stage IV at diagnosis | 298 (83) |
z Recurrent disease | 59 (17) |
First-line chemotherapy | |
3-drug combination (FLOT) | 192 (54) |
2-drug combination (FLO or FLP) | 165 (46) |
Metastatic disease sites | |
Liver | 157 (44) |
Lymph nodes | 219 (61) |
Peritoneum | 93 (26) |
Lung | 60 (17) |
Lauren classification | |
Diffuse/mixed | 170 (48) |
Intestinal | 139 (39) |
Other/Unknown | 48 (13) |
Sampling specimen | |
Biopsy | 238 (67) |
Surgical specimen | 116 (33) |
Unknown | 3 (1) |
Primary tumor | 298 (83) |
Metastatic lesion | 50 (14) |
Unknown | 9 (3) |